Annals of oncology, 2014-10, Vol.25 (10), p.2092-2092
2014
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
- Ist Teil von
- Annals of oncology, 2014-10, Vol.25 (10), p.2092-2092
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2014
- Quelle
- Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0923-7534eISSN: 1569-8041DOI: 10.1093/annonc/mdu257Titel-ID: cdi_proquest_miscellaneous_1566109833
- Format
- –
- Schlagworte
- Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - pathology, Clinical Trials as Topic, Crizotinib, Disease Progression, ErbB Receptors - antagonists & inhibitors, ErbB Receptors - genetics, Humans, Protein Kinase Inhibitors - administration & dosage, Pyrazoles - administration & dosage, Pyridines - administration & dosage, Receptor Protein-Tyrosine Kinases - antagonists & inhibitors, Receptor Protein-Tyrosine Kinases - genetics